Featured
Read our handpicked blogs, curated for you.
|
CMOs do not struggle to justify campaigns; they struggle to prove Marketing ROI with hard numbers the board trusts. If…
|
Pharma marketers in India know the frustration well. Campaigns stall not because the idea is weak, but because the…
|
For Indian pharma, HCP engagement is no longer about reach; it’s about relevance and measurable impact. Boards want to…
Recent releases
|
MLR in healthcare: How to cut approval time by half without risk
Every healthcare marketer in India knows the pain of the MLR cycle. Content is drafted, sent for review, marked up, revised, sent back again, and weeks later, the campaign is still waiting for…
|
How to finally prove ROI in pharma marketing
Every pharma CMO in India has faced the same boardroom moment: a director asks, “We’ve spent ₹50 crores on marketing this year. What’s the ROI?” The room falls silent. Spreadsheets shuffle. Activity…
|
Winning HCP engagement beyond metro cities
Healthcare in India doesn’t stop at Mumbai, Delhi, or Bangalore. Beyond the metros lies the bulk of India’s medical ecosystem: doctors in Tier 2 and Tier 3 cities who prescribe at scale, influence…
|
Why pharma marketing still flies blind in India
Indian pharma marketing is at a crossroads. Budgets are rising, regulations are tightening, and digital adoption is accelerating. Yet when senior leaders are asked the simplest boardroom question: “…
